hrp0095p1-346 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

In between isolated premature thelarche and central precocious puberty: when DHEAS makes the difference

Rodari Giulia , Collini Valentina , Giacchetti Federico , Profka Eriselda , Dall'Antonia Alberta , Arosio Maura , Giavoli Claudia

Background: Precocious puberty (PP) in girls is most frequently an idiopathic gonadotropin-releasing hormone (GnRH)-dependent PP, being thelarche the typical first sign. It is well established that increased dehydroepiandrosterone sulphate (DHEAS) levels are associated with premature adrenarche and may characterize PP too. However, its relationship with signs of hypothalamic-pituitary-gonadal (HPG) axis activation and estrogen exposure is still to be elucidate...

hrp0094p2-358 | Pituitary, neuroendocrinology and puberty | ESPE2021

Pubertal induction in girls with hypogonadism: preliminary prospective data of efficacy in patients with/without initial overnight estrogen replacement

Rodari Giulia , Federici Silvia , Persani Luca , Arosio Maura , Bonomi Marco , Giavoli Claudia ,

Background: Pubertal induction in girls with hypogonadism through estrogen replacement therapy (ERT) aims at the development of secondary sexual characteristics, cognitive functions, uterine growth and maturation, bone mass accrual and linear growth. To date, the best induction regimen, capable of assuring both physiological gradual progression through Tanner stages and effective uterine development, is still to be established.Patients a...

hrp0097p1-517 | Growth and Syndromes | ESPE2023

Bridging the gap between short stature and metabolic alterations in children born small for gestational age: an exploratory study

Rodari Giulia , Citterio Valeria , Collini Valentina , Risio Alessandro , Profka Eriselda , Giacchetti Federico , Arosio Maura , Mantovani Giovanna , Giavoli Claudia

Introduction: Children born small for gestational age (SGA) represent a heterogeneous population, displaying different phenotypes for both growth and metabolic status. Low birth length and/or weight increases the risks for not only growth impairment but also for metabolic derangements (cardiovascular disease, hypertension and type 2 diabetes), the latter with an even amplified risk in children with rapid postnatal weight gain. Variability in metabolic paramete...

hrp0098fc10.3 | Multisystem Endocrine Disorders | ESPE2024

Endocrine disorders in a wide cohort of children and adolescents affected by Neurofibromatosis type 1

Collini Valentina , Risio Alessandro , Grilli Federico , Rodari Giulia , Citterio Valeria , Giacchetti Federico , Profka Eriselda , Mantovani Giovanna , Giavoli Claudia

Background: Neurofibromatosis type 1 (NF1) is an autosomal-dominant disorder affecting 1:3000 individuals. Endocrine comorbidities have been reported in 1%-3% of all NF1 patients. In children, central precocious puberty (CPP) is the most frequent endocrinopathy (3%). Other endocrinological problems associated with this condition are short stature, growth hormone (GH) deficiency/excess, calcium-phosphate metabolism derangement and decreased bone mineral density...

hrp0098p2-246 | Pituitary, Neuroendocrinology and Puberty | ESPE2024

The role of insulin-like growth factor-I in predicting growth velocity during GnRH-agonists treatment for central precocious puberty.

Citterio Valeria , Rodari Giulia , Collini Valentina , Risio Alessandro , Comitani Sofia , Profka Eriselda , Giacchetti Federico , Mantovani Giovanna , Giavoli Claudia

Introduction: Central precocious puberty is characterized by early activation of pituitary-gonadal axis, often associated with high levels of insulin-like growth factor-I (IGF-I), together with accelerated growth and bone maturation, which can ultimately lead to a low adult height (HT). Treatment with GnRH-agonists (GnRHa) can help reducing growth acceleration and rate of bone maturation, though not always restoring prepubertal growth velocity. The causes of d...

hrp0095p2-280 | Thyroid | ESPE2022

From overt hyperthyroidism to normal thyroid function in TSH receptor activating mutations: reports of two families with novel pathogenetic variants and suggestion of a phenotypical sexual dimorphism

Citterio Valeria , Giavoli Claudia , Stellaria Grassi Elisa , Rurale Giuditta , Profka Eriselda , Rodari Giulia , Giacchetti Federico , Collini Valentina , Campi Irene , Arosio Maura , Persani Luca

Introduction: Familial non-autoimmune autosomal dominant hyperthyroidism (FNAH) is a rare cause of childhood hyperthyroidism caused by an activating variant of the thyroid stimulating hormone receptor (TSHR) gene. This disorder may occur as a result of an autosomal dominant inheritance or sporadically through de novo variation. The severity of hyperthyroid symptoms is variable and phenotype differences have been described in subjects harbouring the same mutati...

hrp0094p1-122 | Growth A | ESPE2021

Short stature in Protein Arginine Methyltransferase 7 (PRMT7) mutations: first evidences of growth response to rGH treatment

Rodari Giulia , Giacchetti Federico , Villa Roberta , Scuvera Giulietta , Gangi Silvana , Porro Matteo , Bedeschi Maria Francesca , Profka Eriselda , Dall’Antonia Alberta , Arosio Maura , Giavoli Claudia ,

Protein arginine methyltransferase 7 (PRMT7), a member of a family of enzymes that catalyse the transfer of methyl groups from S-adenosyl-L-methionine to nitrogen atoms on arginine residues, is involved in multiple biological processes, such as signal transduction, mRNA splicing, transcriptional control, DNA repair, and protein translocation. Currently, 12 patients with homozygous/compound heterozygous mutations in PRMT7 gene have been described defining the ...

hrp0097p1-99 | GH and IGFs | ESPE2023

Clinicians’ perceptions on ease of use and usefulness of Aluetta® Smartdot™ and comprehensive digital health ecosystem in Italy to support patients receiving r-hGH treatment

Felicia Faienza Maria , Vergani Edoardo , Di Mase Raffaella , Frasca Francesco , Giavoli Claudia , Klain Antonella , Laura Iezzi Maria , Aversa Antonio , Koledova Ekaterina , Rivera Romero Octavio

Background: Aluetta® Smartdot™ (Merck Healthcare KGaA, Darmstadt, Germany) is first of its kind digitally connected smart injection pen device for recombinant-human growth hormone (r-hGH) administration. Aluetta® pen with Smartdot™ knob attachment integrated with Growzen™ digital ecosystem enables healthcare professionals (HCPs) to remotely monitor adherence and achieve optimal clinical outcomes for patients....

hrp0095p1-413 | Adrenals and HPA Axis | ESPE2022

Incidence and severity of Coronavirus Disease 2019 (COVID-19) in children with primary and secondary adrenal insufficiency during the pandemic in Italy

Moracas Cristina , Russo Gianni , Baronio Federico , Ortolano Rita , Rita Stancampiano Marianna , Cavarzere Paolo , Zoller Thomas , Longhi Silvia , Felicia Faienza Maria , Patti Giuseppa , Elisabeth Street Maria , Guzzetti Chiara , Valenzise Mariella , Giavoli Claudia , Salerno Mariacarolina , Capalbo Donatella

Background: Adrenal insufficiency (AI) is a rare condition caused by an inadequate production of glucocorticoids. Preliminary data in adults suggest that AI could be associated with an increased susceptibility to infections; moreover, AI patients are at risk to develop a severe course of infectious diseases and to experience a life-threatening adrenal crisis. The aim of our study is to evaluate the severity and the outcome of COVID-19 in pediatric AI patients ...

hrp0095p1-93 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Measurements of Growth Hormone in neonatal screening cards as a non-invasive and feasible tool: reference values in healthy term newborns.

Giacchetti Federico , Vidali Matteo , Sangiorgio Andrea , Rodari Giulia , Vantaggiato Chiara , Modugno Adriana Di , Morniroli Daniela , Colombo Lorenzo , Profka Eriselda , Dall'Antonia Alberta , Collini Valentina , Ceriotti Ferruccio , Mosca Fabio , Arosio Maura , Lorella Giannì Maria , Giavoli Claudia

Background: Severe congenital growth hormone deficiency (cGHD) is a rare but potentially life-threatening condition. Even though random growth hormone (GH) can confirm cGHD during the first week of life, the diagnosis remains extremely challenging in the absence of reliable reference values in healthy neonates and thus of a best diagnostic cut-off.Aims: First, to provide solid reference values for GH concentrations in te...